Altshuler Shaham Ltd Raises Stake in Edwards Lifesciences Co. (NYSE:EW)

Altshuler Shaham Ltd increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 73.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,641 shares of the medical research company’s stock after acquiring an additional 7,886 shares during the period. Altshuler Shaham Ltd’s holdings in Edwards Lifesciences were worth $1,421,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the company. Turtle Creek Wealth Advisors LLC bought a new position in Edwards Lifesciences in the fourth quarter valued at $34,000. Operose Advisors LLC increased its holdings in shares of Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after buying an additional 452 shares during the period. SRS Capital Advisors Inc. boosted its holdings in Edwards Lifesciences by 292.6% during the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 474 shares during the period. NBC Securities Inc. purchased a new stake in shares of Edwards Lifesciences during the third quarter valued at approximately $52,000. Finally, ORG Partners LLC bought a new position in shares of Edwards Lifesciences in the third quarter worth approximately $66,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Trading Up 2.7 %

Shares of EW traded up $2.33 during trading hours on Thursday, reaching $87.42. 3,421,899 shares of the company traded hands, compared to its average volume of 3,709,712. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The stock’s fifty day moving average price is $90.03 and its 200 day moving average price is $79.73. The firm has a market cap of $52.68 billion, a price-to-earnings ratio of 37.68, a PEG ratio of 3.59 and a beta of 1.10. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Piper Sandler upped their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday, April 26th. Barclays boosted their price target on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a research report on Tuesday. Mizuho lifted their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Finally, Wells Fargo & Company increased their target price on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a research note on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $93.27.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 11,000 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the transaction, the vice president now directly owns 39,503 shares of the company’s stock, valued at $3,390,542.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, VP Donald E. Bobo, Jr. sold 11,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the completion of the transaction, the vice president now directly owns 39,503 shares of the company’s stock, valued at $3,390,542.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Robert W.A. Sellers sold 12,210 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $87.00, for a total value of $1,062,270.00. Following the completion of the sale, the senior vice president now directly owns 13,087 shares of the company’s stock, valued at $1,138,569. The disclosure for this sale can be found here. Insiders sold a total of 230,693 shares of company stock worth $20,310,942 in the last 90 days. 1.27% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.